First rotational IMRT treatment with a Siemens Artiste linear accelerator and RayStation


RaySearch Laboratories AB (publ) announces that the first clinical mARC
treatment, planned with RaySearch’s treatment planning system RayStation®, has
been delivered at Europe Hospitals in Brussels, Belgium. mARC (Modulated Arc) is
a type of rotational IMRT treatment carried out with Siemens Artiste® linear
accelerators, where the beam is kept turned on as the gantry rotates around the
patient. The concept enables as high treatment precision as with ordinary IMRT
but with significantly faster delivery times.

Europe Hospitals is the largest private hospital group in Brussels with 716 stay
-in beds and 200 one-day beds. They employ about 300 medical doctors and 2,000
staff members spread over two sites. Brussels Europe Hospitals run a private
Radiotherapy and Oncology Department. The External Beam Radiotherapy department
is fully equipped for modern external beam and HDR-brachytherapy treatments.

“We acquired RayStation® in 2013 based on the breadth of technology including
support of rotational IMRT for all types of linear accelerators, the high speed
of planning and dose computation, the robustness of optimization and the ease of
analysis. Now we have implemented mARC or rotational IMRT on the Siemens
Artiste® linear accelerators clinically, and on April 17 the first patient
worldwide received an mARC treatment that was planned in RayStation®”, says Dr.
Carl Salembier, Head of the Radiation Oncology department at Brussels Europe
Hospitals.

Alex Rijnders, Chief Medical Physicist at Brussels Europe Hospitals, adds: "We
are happy that we can offer our patients this advanced treatment modality.
Thanks to the powerful capabilities of RayStation®, treatment planning turned
out easy and efficient, leading to optimal solutions and high plan quality. We
are looking forward to further collaboration with RaySearch in exploring the
possibilities offered by the mARC treatment modality, such as hybrid
treatments."

Johan Löf, CEO of RaySearch, comments: “The unique optimization algorithms in
RayStation® enabling rotational therapy with Siemens Artiste® linacs were
developed together with Siemens in 2012. As they have now been validated
clinically, I believe RayStation® is the only modern treatment planning system
that offers adequate support for all advanced treatment modalities from all the
major hardware vendors including Siemens. This capability makes RayStation® a
highly attractive alternative for clinics with Siemens linear accelerators or a
mix of linear accelerators from different vendors.”

About RayStation®
RayStation® integrates all RaySearch’s advanced treatment planning solutions
into a flexible treatment planning system. It combines unique features such as
multi-criteria optimization tools with full support for 4D adaptive radiation
therapy. It also includes functionality such as RaySearch’s market-leading
algorithms for IMRT and VMAT optimization and highly accurate dose engines for
photon, electron and proton therapy. The system is built on the latest software
architecture and has a graphical user interface offering state-of-the-art
usability.

About RaySearch
RaySearch Laboratories is a medical technology company that develops advanced
software solutions for improved radiation therapy of cancer. RaySearch’s
products are mainly sold through license agreements with leading partners such
as Philips, Nucletron, IBA, Varian and Brainlab. To date, 15 products have been
launched through partners and RaySearch’s software is used at 2,500 clinics in
more than 65 countries. In addition, RaySearch offers the proprietary treatment
planning system RayStation® directly to clinics. RaySearch was founded in 2000
as a spin-off from Karolinska Institutet in Stockholm and the company is listed
in the Small Cap segment on NASDAQ OMX Stockholm.

For more information about RaySearch, visit www.raysearchlabs.com

For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-545 061 30
johan.lof@raysearchlabs.com

Anhänge

04304443.pdf
GlobeNewswire